Lincoln National Corp Outlook Therapeutics, Inc. Transaction History

Lincoln National Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$0.22 - $0.66 $56,540 - $169,620	-257,000 Reduced 80.24%	63,300 $24,000
Q2 2023 Aug 04, 2023	BUY	$1.02 - $1.89 $128,520 - $238,140	126,000 Added 64.85%	320,300 $557,000
Q4 2022 Feb 07, 2023	BUY	$0.87 - $1.33 $35,670 - $54,530	41,000 Added 26.74%	194,300 $209,000
Q2 2022 Aug 02, 2022	BUY	$0.91 - $2.01 $45,500 - $100,499	50,000 Added 48.4%	153,300 $156,000
Q4 2021 Jan 26, 2022	SELL	$1.27 - $2.23 $190,500 - $334,500	-150,000 Reduced 59.22%	103,300 $140,000
Q2 2021 Aug 13, 2021	BUY	$1.78 - $2.76 $450,874 - $699,108	253,300 New	253,300 $631,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.17B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.